Production and regulatory issues for theranostics

  • 10:52
Ver Detalles

Recent advances and impending challenges for the radiopharmaceutical sciences in oncology

  • 10:51
Ver Detalles

Systematic Review of the First 40 Cases of 177Lu-PSMA Therapy in the Treatment of Non-prostatic Cancer

  • 10:51
Ver Detalles

Is 161Tb Really Happening?

  • 11:47
Ver Detalles

Granzyme B PET Imaging for Assessment of Disease Activity in Inflammatory Bowel Disease

  • 11:44
Ver Detalles

Clinical Management of Advanced Prostate Cancer: Where Does Radiopharmaceutical Therapy Fit in the Treatment Algorithm?

  • 11:43
Ver Detalles

Noninvasively Deciphering the Immunosuppressive Tumor Microenvironment Using Galectin-1 PET to Inform Immunotherapy Responses

  • 11:42
Ver Detalles

First-in-Human Safety, Imaging, and Dosimetry of a Carbonic Anhydrase IX–Targeting Peptide, [68Ga]Ga-DPI-4452, in Patients with Clear Cell Renal Cell Carcinoma

  • 17:39
Ver Detalles

99mTc‑labeled FAPI compounds for cancer and infammation: from radiochemistry to the first clinical applications

  • 17:31
Ver Detalles

Desarrollo y validación de un procedimiento alternativo para realizar los controles de pureza radioquímica de radiofármacos de 99mTc con un contador Geiger Müller

  • 17:30
Ver Detalles

First-in-Human 212Pb-PSMA–Targeted α-Therapy SPECT/CT Imaging in a Patient with Metastatic Castration-Resistant Prostate Cancer

  • 10:08
Ver Detalles

Risk Management in Good Manufacturing Practice (GMP) Radiopharmaceutical Preparations

  • 12:00
Ver Detalles

Effectiveness and Safety of Retreatment with 177Lu-DOTATATE in Patients with Progressive Neuroendocrine Tumors: A Retrospective Real-World Study in the United States

  • 10:57
Ver Detalles

Radionuclide Theranostics in Neuroendocrine Neoplasms: AnUpdate

  • 10:25
Ver Detalles

Prostate Cancer Theranostics With 177Lu-PSMA

  • 10:23
Ver Detalles

PET/TC con FAPI: procedimiento y revisión de la evidencia en oncología

  • 11:29
Ver Detalles
La Radiofarmacia es la especialidad sanitaria que estudia los aspectos farmacéuticos, químicos, bioquímicos, biológicos y físicos de los radiofármacos.
  • Calle Velázquez,10 28001 Madrid
  • secretaria@serfaradiofarmacia.com
  • +34 910 601 760
© 2023 - Radiofarmacia - Sociedad Española de Radiofarmacia
Scroll al inicio